Evidence map›Paper›PMID 36866436›Full record

ArticleCardiovascular research2023

Pyruvate dehydrogenase kinase regulates vascular inflammation in atherosclerosis and increases cardiovascular risk.

Maria J Forteza, Martin Berg, Andreas Edsfeldt, Jangming Sun, Roland Baumgartner, Ilona Kareinen, Felipe Beccaria Casagrande, Ulf Hedin, Song Zhang, Ivan Vuckovic and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 4 countries.

Maria J FortezaCenter for Molecular Medicine, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Instutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.
Martin BergCenter for Molecular Medicine, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Instutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.
Andreas EdsfeldtCardiovascular Research Translational Studies, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 35, 20 502, Malmö, Sweden.ORCID 0000-0002-2691-9192
Jangming SunCardiovascular Research Translational Studies, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 35, 20 502, Malmö, Sweden.
Roland BaumgartnerCenter for Molecular Medicine, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Instutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.
Ilona KareinenCenter for Molecular Medicine, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Instutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.ORCID 0000-0002-2528-9264
Felipe Beccaria CasagrandeCenter for Molecular Medicine, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Instutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.
Ulf HedinDepartment of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.ORCID 0000-0001-9212-3945
Song ZhangMayo Clinic Metabolomics Core, Mayo Clinic, 200, First St. SW Rochester, MN 55905, USA.
Ivan VuckovicMayo Clinic Metabolomics Core, Mayo Clinic, 200, First St. SW Rochester, MN 55905, USA.
Petras P DzejaDepartment of Cardiovascular Medicine, Mayo Clinic, 200, First St. SW Rochester, MN 55905, USA.
Konstantinos A PolyzosCenter for Molecular Medicine, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Instutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.
Anton GisteråCenter for Molecular Medicine, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Instutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.ORCID 0000-0002-4614-8030
Mette TrauelsenSection for Metabolic Receptology, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3A, 2200, Copenhagen, Denmark.
Thue W SchwartzSection for Metabolic Receptology, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3A, 2200, Copenhagen, Denmark.
Lea DibKennedy Institute of Rheumatology, University of Oxford, Roosevelt Dr, Headington, Oxford OX3 7FY, UK.ORCID 0000-0001-5889-4738
Joerg HerrmannDepartment of Cardiovascular Medicine, Mayo Clinic, 200, First St. SW Rochester, MN 55905, USA.
Claudia MonacoKennedy Institute of Rheumatology, University of Oxford, Roosevelt Dr, Headington, Oxford OX3 7FY, UK.ORCID 0000-0003-1985-4914
Ljubica MaticDepartment of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.
Isabel GonçalvesCardiovascular Research Translational Studies, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 35, 20 502, Malmö, Sweden.
Daniel F J KetelhuthCenter for Molecular Medicine, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Instutet, BioClinicum, Solnavägen 30, Solna, 17 164, Stockholm, Sweden.ORCID 0000-0002-0087-116X
Karolinska University Hospital · SEMayo Clinic · USLund University · SEUniversity of Copenhagen · DKUniversity of Oxford · GB

Funding

TECHNOLOGY NMR SPECTROSCOPYU24DK100469 · NIDDK · MAYO CLINIC ROCHESTER · PI NAIR, K SREEKUMARAN · 2013 to 2017
$9.0M
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) TrialR01CA233610 · NCI · MAYO CLINIC ROCHESTER · PI HERRMANN, JOERG, RUDDY, KATHRYN JEAN · 2019 to 2024
$4.3M
NCI NIH HHS R01 CA233610NIDDK NIH HHS U24 DK100469
6 · The paper itself

Abstract

aimsRecent studies have revealed a close connection between cellular metabolism and the chronic inflammatory process of atherosclerosis. While the link between systemic metabolism and atherosclerosis is well established, the implications of altered metabolism in the artery wall are less understood. Pyruvate dehydrogenase kinase (PDK)-dependent inhibition of pyruvate dehydrogenase (PDH) has been identified as a major metabolic step regulating inflammation. Whether the PDK/PDH axis plays a role in vascular inflammation and atherosclerotic cardiovascular disease remains unclear. METHODS AND

resultsGene profiling of human atherosclerotic plaques revealed a strong correlation between PDK1 and PDK4 transcript levels and the expression of pro-inflammatory and destabilizing genes. Remarkably, the PDK1 and PDK4 expression correlated with a more vulnerable plaque phenotype, and PDK1 expression was found to predict future major adverse cardiovascular events. Using the small-molecule PDK inhibitor dichloroacetate (DCA) that restores arterial PDH activity, we demonstrated that the PDK/PDH axis is a major immunometabolic pathway, regulating immune cell polarization, plaque development, and fibrous cap formation in Apoe-/- mice. Surprisingly, we discovered that DCA regulates succinate release and mitigates its GPR91-dependent signals promoting NLRP3 inflammasome activation and IL-1β secretion by macrophages in the plaque.

conclusionsWe have demonstrated for the first time that the PDK/PDH axis is associated with vascular inflammation in humans and particularly that the PDK1 isozyme is associated with more severe disease and could predict secondary cardiovascular events. Moreover, we demonstrate that targeting the PDK/PDH axis with DCA skews the immune system, inhibits vascular inflammation and atherogenesis, and promotes plaque stability features in Apoe-/- mice. These results point toward a promising treatment to combat atherosclerosis.

Indexed as

AtherosclerosisCardiovascular DiseasesPyruvate Dehydrogenase Acetyl-Transferring KinaseAnimalsHeart Disease Risk FactorsHumansInflammationMiceMice, Knockout, ApoERisk FactorsPyruvate Dehydrogenase Acetyl-Transferring KinaseatherosclerosisCVDimmunometabolisminflammationPDK

Identifiers

PMID36866436
PMCPMC10318388
OpenAlexW4323037615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.